Use of atypical antipsychotics in the treatment of schizophrenia in the Brazilian National Health System: a cohort study, 2008-2017

Use of atypical antipsychotics in the treatment of schizophrenia in the Brazilian National Health System: a cohort study, 2008-2017

Abstract Objective: to investigate sociodemographic and clinical characteristics of users of atypical antipsychotics receiving care via the Specialized Component of Pharmaceutical Assistance (Componente Especializado da Assistência Farmacêutica - CEAF), for the treatment of schizophrenia in Brazil...

Full description

Bibliographic Details
Main Authors:	Izabela Fulone, Marcus Tolentino Silva, Luciane Cruz Lopes
Format:	Article
Language:	English
Published:	Ministério da Saúde do Brasil 2023-03-01
Series:	Epidemiologia e Serviços de Saúde
Subjects:	Antipsychotics Brazilian National Health System Schizophrenia Brazil Off-Label Use Cohort Studies
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2237-96222023000100308&lng=en&tlng=en

Similar Items

Switching Between Second-Generation Antipsychotics in Patients with Schizophrenia and Schizoaffective Disorder: 10-Year Cohort Study in Brazil
by: Izabela Fulone, et al.
Published: (2021-05-01)

Atypical antipsychotics in the treatment of schizophrenia
by: Swiss Medical Weekly
Published: (2003-02-01)

Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia
by: I. A. Vilyum, et al.
Published: (2018-08-01)

Metabolic disturbances in patients with paranoid schizophrenia treated with atypical antipsychotic drugs
by: Leonid Mikhaylovich Bardenshteyn, et al.
Published: (2010-06-01)

Effect of Atypical Antipsychotic Medications on the Risk of Obstructive Sleep Apnea in Individuals With Schizophrenia
by: Habibolah Khazaie, et al.
Published: (2022-09-01)

Effects of zinc sulfate on schizophrenia symptoms in patients undergoing atypical antipsychotic pharmacotherapy
by: Forouzan Behrouzian, et al.
Published: (2022-01-01)

Antipsychotic prescribing patterns in children and adolescents attending Australian general practice in 2011 and 2017
by: Julie Klau, et al.
Published: (2024-03-01)

Pharmacoeconomic comparison of ziprasidone with other atypical oral antipsychotic agents in schizophrenia
by: Andrea Fagiolini, et al.
Published: (2011-11-01)

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome
by: Sang Won Jeon, et al.
Published: (2017-10-01)

Off-label prescribing of antipsychotics: prescribing practices and clinical experiences of Finnish physicians
by: N. Rautio, et al.
Published: (2022-06-01)

Clozapine: A special case of an atypical antipsychotic
by: Elina Marinho
Published: (2024-04-01)

Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
by: Eiji Kirino
Published: (2017-11-01)

Polypharmacy Management of Antipsychotics in Patients with Schizophrenia
by: Hiroyuki Kamei
Published: (2022-11-01)

Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics
by: Anastasiia S. Boiko, et al.
Published: (2021-05-01)

Atypical Antipsychotics Induced Metabolic Syndrome
by: Aysegul Demirel, et al.
Published: (2015-03-01)

Effectiveness of antipsychotics in schizophrenia with comorbid substance use disorder
by: M. Lähteenvuo, et al.
Published: (2021-04-01)

Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia
by: Davide Amato, et al.
Published: (2019-05-01)

Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia
by: Kristian S. Hill, et al.
Published: (2009-04-01)

The effects of antipsychotic drugs on depression level in patients with schizophrenia: clozapine vs. other atypical antipsychotics
by: Hülya Ertekin, et al.
Published: (2016-08-01)

Analysis of Oral versus Long-acting Injectable Antipsychotics in the Maintenance of Schizophrenia
by: O. Vasiliu
Published: (2022-06-01)

Antipsychotic medication non-adherence among schizophrenia patients in Central Ethiopia
by: Minale Tareke, et al.
Published: (2018-03-01)

Evaluation of naltrexone augmentation to the antipsychotic drugs on positive and negative symptoms of schizophrenia
by: Javad Setareh, et al.
Published: (2008-01-01)

Influence of antipsychotic medications on hyperlipidemia risk in patients with schizophrenia: evidence from a population-based cohort study and in vitro hepatic lipid homeostasis gene expression
by: Tien-Yuan Wu, et al.
Published: (2023-06-01)

Off–label long acting injectable antipsychotics in real–world clinical practice: a cross-sectional analysis of prescriptive patterns from the STAR Network DEPOT study
by: Armando D’Agostino, et al.
Published: (2022-06-01)

Antipsychotics-related hyperprolactinaemia among patients with schizophrenia in Maiduguri
by: Falmata B. Shettima, et al.
Published: (2024-02-01)

Schizophrenia long-acting antipsychotics initiation index (SLAAII)
by: P. Ifteni, et al.
Published: (2021-04-01)

Hyperhomocysteinemia in Treatment with Atypical Antipsychotics is Independent of Metabolic Syndrome
by: Emre Sarandöl, et al.
Published: (2023-12-01)

Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review
by: Xu H, et al.
Published: (2019-07-01)

The efficacy, acceptability, and safety of five atypical antipsychotics in patients with first-episode drug-naïve schizophrenia: a randomized comparative trial
by: Congjie Wang, et al.
Published: (2017-12-01)

Effects of Psychostimulants and Antipsychotics on Serum Lipids in an Animal Model for Schizophrenia
by: Banny Silva Barbosa Correia, et al.
Published: (2021-02-01)

Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia
by: Chadia Haddad, et al.
Published: (2023-01-01)

Prescription of antipsychotics and prevalence of metabolic syndrome in Vietnamese inpatients with schizophrenia
by: Nguyen Thi Minh Thuan, et al.
Published: (2022-07-01)

Early Markers in Resistant Schizophrenia: Effect of the First Antipsychotic Drug
by: Georgi Panov Panov
Published: (2022-03-01)

Antipsychotics and risk of natural death in patients with schizophrenia
by: Chen Y, et al.
Published: (2019-07-01)

Treatment Responses of Cognitive Function and Plasma Asymmetric Dimethylarginine to Atypical Antipsychotic in Patients With Schizophrenia
by: Zhi-min Yu, et al.
Published: (2019-01-01)

A comparison of depot and oral atypical antipsychotics in terms of metabolic syndrome markers
by: Demet Sağlam Aykut, et al.
Published: (2018-07-01)

Altered mitochondrial lymphocyte in overweight schizophrenia patients treated with atypical antipsychotics and its association with cognitive function
by: Yaoyao Zhang, et al.
Published: (2024-01-01)

Anti-stress Properties of Atypical Antipsychotics
by: Alice Sanson, et al.
Published: (2020-10-01)

Off-label prescribing of antipsychotics in a Danish child and adolescent mental health center: A register-based study
by: Kristine Tofting Korno, et al.
Published: (2018-01-01)

Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia
by: Riboldi I, et al.
Published: (2022-12-01)